Items Tagged ‘Breast Cancer’

December 28, 2018

Immunotherapy Offers New Hope in Triple Negative Breast Cancer

By

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results were seen with the PD-L1 drug Tecentriq used in combination with chemotherapy for the treatment of triple negative breast cancer. […]

View full entry

Tags: Breast Cancer, News


December 21, 2018

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

By

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past month. Specifically, Herzuma is approved to treat: Adjuvant breast cancer of HER2 overexpressing node positive or node negative (ER/PR negative […]

View full entry

Tags: Breast Cancer, News


December 19, 2018

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

By

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment in the first 30 days after surgery, according to a retrospective study presented at the 2018 San Antonio Breast […]

View full entry

Tags: Breast Cancer, News


December 12, 2018

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer

By

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine (T-DM1) had improved disease-free survival compared to patients who received adjuvant trastuzumab, according to the results from the phase 3 KATHERINE trial. Previously reported […]

View full entry

Tags: Breast Cancer, News


December 11, 2018

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

By

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8. Hot flashes, a common symptom of menopause, can be more severe in breast […]

View full entry

Tags: Breast Cancer, News


December 10, 2018

Choice of surgery may affect quality of life for young breast cancer survivors

By

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center. The findings, presented at the San Antonio Breast Cancer Symposium, underscore the importance of counseling patients about the […]

View full entry

Tags: Breast Cancer, News


July 23, 2018

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

By

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the […]

View full entry

Tags: Breast Cancer, News


July 9, 2018

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

By

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American […]

View full entry

Tags: Breast Cancer, Dana Farber Cancer Center, Harvard, News, premenopausal breast cancer treatment


June 21, 2018

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation

By

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy in patients with inherited BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. About Talazoparib Talazoparib is an investigational anti-cancer […]

View full entry

Tags: Breast Cancer, News


April 19, 2018

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer

By

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For the study, 3697 postsurgical patients with invasive hormone receptor–positive breast cancer were enrolled from 76 Italian public healthcare institutions between March 9, […]

View full entry

Tags: anastrozole, Arimidex, aromasin, Breast Cancer, exemestane, Femara, hormone-receptor positive, letrozole, News, switch schedule


March 26, 2018

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer

By

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early stage breast cancer at high risk of recurrence. About Perjeta Breast cancer is the second leading cause of cancer-related death among […]

View full entry

Tags: Breast Cancer, HER-2, neu positive, News, perjeta, pertuzumab


March 20, 2018

At-home Genetic Testing may be Convenient, but it isn’t Complete

By

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally changing our lives for the better — giving us more time and choices — at-home genetics kits that reveal information about the risk of developing […]

View full entry

Tags: 23andme, brca, Breast Cancer, genetic testing, News


March 12, 2018

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. About VerzenioTM Verzenio is an inhibitor of cyclin-dependent kinases […]

View full entry

Tags: 4 & 6, Breast Cancer, CDK, inhibitor of cyclin-dependent kinases, News, Verzenio


February 21, 2018

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer

By

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published by a multi-institutional team of researchers.1,2 Although TNBC represents just 10-15 percent of all breast diagnoses, the disease is responsible for 35 […]

View full entry

Tags: Breast Cancer, Liquid Biopsy, News, Triple Negative Breast Cancer


February 13, 2018

Kisqali Combination Promising for Pre-menopausal Hormone Receptor Positive Breast Cancer

By

CancerConnect News: The CDK4/6 inhibitor Kisqali (ribociclib) has been given breakthrough status by the US Food and Drug Administration as an initial endocrine-based treatment for of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. Results from […]

View full entry

Tags: Breast Cancer, CDK4/6 inhibitor, kisqali, News, ribociclib, treatment